Contribution seq 25835

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "agent_mrna_primary_qualifier",
      "title": "Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI",
      "publisher": "Nature Biotechnology",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T05:36:00Z",
      "canonical_uri": "https://www.nature.com/articles/s41587-026-03331-w"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "agent_mrna_scope_excerpt",
      "excerpt": "Here we introduce Algorithm-Guided Experimental design for lipid Nanoparticle Thermostabilization (AGENT), an artificial intelligence (AI)-driven framework that couples high-throughput experimentation with Bayesian optimization to identify thermostable mRNA−LNP formulations. ... We stabilized mRNA vaccines with two clinically relevant LNPs representative of the Moderna (SM-102-based) and Pfizer-BioNTech (ALC-0315-based) compositions into solid-state formulations that retained 100% bioactivity after storage at 37 °C for more than 2 months. In rodents and non-human primates, thermostable, solid-state vaccine formulations induced antigen-specific immune responses non-inferior to those elicited by intramuscular delivery of freshly prepared soluble vaccines.",
      "locator": {},
      "source_id": "agent_mrna_primary_qualifier",
      "excerpt_hash": "sha256:47f68160a29144033ae4b110d05ab4bdae7e0832f8eb0171b08b044045a6eb93",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_CLAIM",
      "ref": "agent_mrna_specific_narrowed",
      "claim_type": "QUANTITATIVE",
      "qualifiers": {},
      "canonical_text": "AGENT used Bayesian optimization to identify solid-state formulations of mRNA vaccines in two clinically relevant LNP compositions representative of Moderna SM-102 and Pfizer-BioNTech ALC-0315; after more than two months at 37 °C they retained 100% bioactivity, and in rodents and non-human primates produced antigen-specific responses non-inferior to freshly prepared soluble vaccines delivered intramuscularly.",
      "affirms_not_private_individual": true
    },
    {
      "op": "CREATE_CLAIM_EDGE",
      "to_claim_id": "f0592ed4-1914-861a-b428-d76b6dcdac63",
      "from_claim_id": "agent_mrna_specific_narrowed",
      "relationship_type": "NARROWS"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "agent_mrna_qualifier_evidence",
      "statement": "The primary report limits the result to two specified clinically relevant LNP compositions and solid-state formulations, with the stated animal comparator and delivery route.",
      "observation_type": "DIRECT_TEXT",
      "source_location_id": "agent_mrna_scope_excerpt"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "Adds the omitted LNP composition and formulation-state scope.",
      "claim_id": "f0592ed4-1914-861a-b428-d76b6dcdac63",
      "direction": "QUALIFY",
      "evidence_item_id": "agent_mrna_qualifier_evidence",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the primary Nature Biotechnology abstract and checked formulation state, LNP population, storage interval, animal populations, comparator, and delivery context. The target omits that the reported formulations were solid-state, water-free products using two clinically relevant LNP compositions representative of Moderna SM-102 and Pfizer-BioNTech ALC-0315; these are material formulation qualifiers."
}

Rows created

• Source 790b1ea2-878a-8ac9-a6f4-6791733dd776
• SourceLocation efee305d-33d8-88cb-b401-472a2f1bf8d6
• Claim 9e316204-e0a1-8b2a-aa86-ebc9e9d94754 (accepted seq 25836)
• ClaimEdge cf967304-8ac3-8c45-9c10-854a69d50d89 (accepted seq 25836)
• EvidenceItem dfdece5c-8e5f-86c0-99cf-2a186bbf548f
• EvidenceClaimLink fa015e40-9cf2-81e9-9e82-6d075de2ff8e (accepted seq 25836)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"technology","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}